Actively Recruiting
Comparing Neoadjuvant Immunochemotherapy Plus Surgery Versus Standard Surgery and Adjuvant Therapy for Locally Advanced Oral Squamous Cell Carcinoma A Multicenter Randomized Phase 3 Trial
Led by Lai-ping Zhong · Updated on 2026-09-21
134
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the effectiveness of neoadjuvant immunochemotherapy using tislelizumab, albumin paclitaxel, and cisplatin followed by radical surgery and adjuvant therapy compared to standard treatment in patients with locally advanced and operable oral squamous cell carcinoma LAOSCC. This phase 3 randomized trial aims to evaluate whether this combined approach improves survival outcomes over the current standard care. Previous studies suggested better pathological response and safety with neoadjuvant immunochemotherapy, but larger controlled trials are needed to confirm these findings. Participants are randomly assigned to either receive neoadjuvant immunochemotherapy with albumin paclitaxel, cisplatin, and tislelizumab for two 3-week cycles before surgery, followed by radical surgery and adjuvant radiotherapy or chemoradiotherapy plus a year of maintenance tislelizumab, or to undergo standard radical surgery and adjuvant therapy without neoadjuvant treatment. Surgery involves removing the primary tumor and neck lymph nodes with defined safety margins. Postoperative radiotherapy starts 4 to 6 weeks after surgery, with possible concurrent chemotherapy for high-risk cases. During the study, participants undergo medical history collection, tumor assessments including imaging before surgery, and pathological examination after surgery. Follow-up occurs every three months for two years, then less frequently up to five years or more. Researchers will measure 2-year event-free and overall survival as primary outcomes, plus disease-free survival and major pathological response. Monitoring continues until death or data cutoff, assessing long-term benefits and safety of the treatments.
CONDITIONS
Brief Title
Neoadjuvant Immunochemotherapy for LAOSCC
Research Team
L
Lai-ping Zhong, MD, PhD
Y
Ying-ying Huang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here